CLS launches its Focal Laser Ablation system for prostate cancer in France in collaboration with MTEC Company

Lund, Sweden, May 14, 2024 - Clinical Laserthermia Systems AB (publ) ("CLS" or "the Company") today announced it has entered into an exclusive distribution agreement with MTEC Company ("MTEC") to market and sell the CLS TRANBERG® product portfolio in France.

Since December 2023 the TRANBERG system is being used in the French national study IRMPROFT. Based on the growing interest for focal therapies in France, CLS is now entering into an exclusive distribution agreement with MTEC, a national French company with long history and experience in the field of clinical lasers, specifically in the urology field.

"The TRANBERG product portfolio perfectly complements our current offering in laser technology in urological oncology," said Eric GIRARD, CEO of MTEC. "We can now offer our large existing customer base and all new physicians, a new laser technology platform designed to treat localized prostate cancer in the most precise and accurate way."

CLS and MTEC are now launching the TRANBERG system in France for Ultrasound image-guided focal laser ablation (FLA) of localized prostate cancer using temperature control. Next step in the market launch is participation in the national scientific BPH/Prostate meeting in Bordeaux, 23-24 May, where the TRANBERG system will be displayed by MTEC, with support from CLS. This meeting brings together key opinion leaders within prostate cancer field and will be an excellent platform for the broader market introduction in France. 

According to Perjan Pleunis, VP Sales Europe, this is a small but important first commercial milestone in the French market for CLS: "France is a very important market for CLS. With our presence on a local conference we show our commitment, not only to our new commercial partner, but also to some of the most influential specialists in the French market. I am looking forward to the collaboration with MTEC, and I´m convinced that their competence and network will contribute to a successful introduction of the CLS TRANBERG system in France."

About prostate cancer

About 1,400,000 new cases per year of prostate cancer are reported worldwide with approximately 350.000 of them within EU and 60 000 in France, according to WHO. Although the landscape of prostate cancer treatment shows several treatment options, there is still an important unmet need for patients with localized prostate cancer who progressed to intermediate risk stage. The currently available surgical options show significant risks and side effects related to urinary and erectile functions and quality of life.

 

For more information, please contact:

Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)

Phone: [phone]

E-mail: [e-mail]

 

About CLS and TRANBERG

Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®, the Company's interstitial laser thermotherapy for immunostimulant ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB.

For more information about CLS, please visit the Company's website: www.clinicallaser.se.

 

About MTEC

MTEC, a French company established in 1994, continues its legacy of providing innovative medical equipment solutions to healthcare professionals and institutions across France. With a focus on delivering value-added products, MTEC has built a reputation for reliability and excellence over the past three decades.

Since its beginning, MTEC has specialized in the distribution of medical and surgical lasers, refining our expertise over the past seventeen years. Laser technology is deeply embedded in our identity, guiding our commitment to delivering innovative solutions to healthcare professionals.

The company's expertise in urology and prostate pathology treatment is widely recognized. To promote new surgical procedures and techniques, MTEC actively fosters strong partnerships with industry leaders and key opinion leaders, driving advancements in surgical innovation and practice.

MTEC's dedication to customer satisfaction is reflected in its highly competent support team, ensuring responsive and personalized service. Upholding principles of quality, ethics, and professionalism, MTEC remains attentive to the evolving needs of its customers and patients.

"We take pride in our long-standing relationships and our ability to provide tailored solutions to meet the diverse needs of the medical community," says Eric Girard, CEO of MTEC. "As we look to the future, MTEC remains devoted to driving innovation and delivering outstanding value to our partners."

For more information about MTEC, please visit the Company's website: Mtec-company - Votre solution biomédicale .

https://news.cision.com/cls/r/cls-launches-its-focal-laser-ablation-system-for-prostate-cancer-in-france-in-collaboration-with-mte,c3979047

https://mb.cision.com/Main/11591/3979047/2795409.pdf

(c) 2024 Cision. All rights reserved., source Press Releases - English